Enduro Genetics and the EIC Accelerator: Addicted to Production

Enduro Genetics, co-founded in Copenhagen in 2019 by Peter Rugbjerg and now led by CEO Christian Munch, makes Enduro Sense, a genetic plug-in that keeps engineered microbes productive during large-scale fermentation. Its EIC project said "fermentation scale-up remains a massive challenge" and that it was "ready to perform large scale demonstrations with commercial strains from industrial partners", according to CORDIS.

The European Innovation Council granted €1,815,296 towards a €2.59 million project from April 2023 to March 2025. The final report says Enduro screened "hundreds of new strain candidates", and that several industrial strains "with significantly improved production stability and titer" were validated in bioreactors. It says the results "helped secure Series A investment", while "successes at industrial scale" were "set to be reached in the coming year". In February 2025 Enduro raised a €12 million Series A from Supernova Invest, NOON Ventures and Sandwater.

Where Enduro Genetics Stands Now

Enduro says it is "already working with global biotechnology leaders to transform production" and targets a biomanufacturing market it puts at €400 billion, covering enzymes, biodegradable materials, alternative proteins and pharmaceuticals. The Series A is to expand its platform and scale commercialisation. It has not named customers or announced an industrial-scale deployment on its news page.

The Technology: Making Cells Depend on Their Job

In big fermenters, engineered microbes mutate and non-producing cells outgrow the productive ones, so yields drop over a production run. Enduro Sense, the company says, "addicts" cells to high production, so that only cells that keep making the product thrive. The report says it worked across different organisms and product types.

What the EIC Project Promised, and What CORDIS Shows

The project promised large-scale demonstrations with commercial strains. The report documents implementation in partners' strains and validation in what it calls "scale-down bioreactor operational environments". Demonstrations at full industrial scale were not reported by the end of the project. CORDIS lists the project as closed.

1. Partner strain integrationDeliveredHundreds of candidates.
2. Bioreactor validationDeliveredScale-down reactors.
3. Industrial-scale demonstrationPending"In the coming year".
4. Follow-on investmentDelivered€12M Series A.

The Money

Enduro's 2024 annual report shows gross profit doubling to DKK 4.47 million and a loss of DKK 3.35 million, the same as in 2023. Equity jumped to DKK 99.8 million, mostly because of DKK 90.1 million of other receivables at year end, while cash was DKK 4.5 million; the report does not break these down in its summary.

What Cannot Be Checked

Why Europe Should Care

Europe has named industrial biotechnology a key enabling technology, and scale-up is where many bioprocesses fail. A tool that keeps yields up in large fermenters could make European biomanufacturing cheaper. The EIC paid for the step that convinced private investors.

The Verdict

Enduro Genetics and the EIC have not been asked for comment for this article. It is based entirely on public records and published statements, linked throughout.